Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:INMBNASDAQ:KRONNASDAQ:MOLNNASDAQ:RAPT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINMBINmune Bio$7.48+1.6%$7.54$4.32▼$10.50$171.92M1.63264,099 shs177,612 shsKRONKronos Bio$0.67-0.4%$0.78$0.65▼$1.60$40.79M1.75312,326 shs66,034 shsMOLNMolecular Partners$3.86+7.7%$3.94$3.36▼$12.70$155.65M1.1520,868 shs538 shsRAPTRAPT Therapeutics$0.90-3.4%$0.96$0.71▼$4.60$118.93M-0.041.28 million shs162,315 shs The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINMBINmune Bio0.00%-1.87%-6.24%-8.34%-23.73%KRONKronos Bio+0.15%-2.40%-25.31%-31.48%-15.53%MOLNMolecular Partners+0.37%+3.34%+6.63%-20.08%-4.96%RAPTRAPT Therapeutics-4.38%+8.41%+2.68%-18.39%-76.45%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINMBINmune Bio1.8596 of 5 stars3.60.00.00.02.71.70.6KRONKronos Bio3.6964 of 5 stars3.25.00.00.03.03.31.3MOLNMolecular Partners2.5218 of 5 stars3.84.00.00.02.20.00.6RAPTRAPT Therapeutics3.8405 of 5 stars3.21.00.04.22.61.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINMBINmune Bio 3.17Buy$22.80205.02% UpsideKRONKronos Bio 2.33Hold$1.63142.90% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00211.28% UpsideRAPTRAPT Therapeutics 2.33Hold$3.00233.70% UpsideCurrent Analyst Ratings BreakdownLatest KRON, INMB, MOLN, and RAPT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025RAPTRAPT TherapeuticsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$2.00 ➝ $1.005/22/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$6.003/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/10/2025RAPTRAPT TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 5/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINMBINmune Bio$50K3,436.11N/AN/A$2.07 per share3.61KRONKronos Bio$9.19M4.44N/AN/A$2.73 per share0.25MOLNMolecular Partners$2.23M69.73N/AN/A$5.41 per share0.71RAPTRAPT Therapeutics$1.53M77.73N/AN/A$4.27 per share0.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINMBINmune Bio-$30.01M-$1.93N/AN/AN/AN/A-117.48%-78.96%8/7/2025 (Estimated)KRONKronos Bio-$112.67M-$1.07N/AN/AN/A-867.66%-64.55%-48.18%8/14/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/ARAPTRAPT Therapeutics-$116.80M-$2.40N/AN/AN/AN/A-89.10%-76.13%8/14/2025 (Estimated)Latest KRON, INMB, MOLN, and RAPT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/8/2025Q1 2025INMBINmune Bio-$0.43-$0.43N/A-$0.43N/A$0.05 million5/8/2025Q1 2025RAPTRAPT Therapeutics-$0.31-$0.08+$0.23-$0.08N/AN/A3/27/2025Q4 2024INMBINmune Bio-$0.54-$0.40+$0.14-$0.40N/AN/A3/18/2025Q4 2024KRONKronos Bio-$0.30-$0.43-$0.13-$0.43$1.00 million$2.27 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/A3/6/2025Q4 2024RAPTRAPT Therapeutics-$0.45-$1.14-$0.69-$1.14N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINMBINmune BioN/AN/AN/AN/AN/AKRONKronos BioN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ARAPTRAPT TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINMBINmune BioN/A2.592.59KRONKronos BioN/A8.328.32MOLNMolecular PartnersN/A14.3314.33RAPTRAPT TherapeuticsN/A9.909.90Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINMBINmune Bio12.72%KRONKronos Bio64.09%MOLNMolecular Partners26.55%RAPTRAPT Therapeutics99.09%Insider OwnershipCompanyInsider OwnershipINMBINmune Bio35.20%KRONKronos Bio24.40%MOLNMolecular Partners5.93%RAPTRAPT Therapeutics2.36%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINMBINmune Bio1022.98 million14.37 millionOptionableKRONKronos Bio10060.97 million45.62 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableRAPTRAPT Therapeutics80132.29 million32.65 millionOptionableKRON, INMB, MOLN, and RAPT HeadlinesRecent News About These CompaniesWhat is HC Wainwright's Forecast for RAPT Q2 Earnings?May 27 at 1:18 AM | marketbeat.com12 Health Care Stocks Moving In Friday's Intraday SessionMay 25, 2025 | benzinga.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to Strong-Buy at HC WainwrightMay 25, 2025 | americanbankingnews.comRAPT Therapeutics (NASDAQ:RAPT) Upgraded to "Hold" at Wall Street ZenMay 24, 2025 | marketbeat.comUBS Group Issues Pessimistic Forecast for RAPT Therapeutics (NASDAQ:RAPT) Stock PriceMay 24, 2025 | marketbeat.comRAPT Therapeutics (NASDAQ:RAPT) Earns Buy Rating from HC WainwrightMay 24, 2025 | marketbeat.com11,764,000 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Acquired by RTW Investments LPMay 18, 2025 | marketbeat.comRapt Therapeutics (RAPT) Upgraded to Buy: Here's What You Should KnowMay 16, 2025 | zacks.com13,135,260 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Orbimed Advisors LLCMay 15, 2025 | marketbeat.comRAPT Therapeutics, Inc. (NASDAQ:RAPT) Given Average Rating of "Hold" by AnalystsMay 11, 2025 | marketbeat.comDeep Track Capital LP Invests $9.50 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comColumn Group LLC Lowers Stock Holdings in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 9, 2025 | marketbeat.comRAPT Therapeutics Reports First Quarter 2025 Financial ResultsMay 8, 2025 | globenewswire.comWhy RAPT Therapeutics, Inc.’s (RAPT) Stock Is Down 5.55%May 8, 2025 | aaii.comBVF Inc. IL Acquires New Position in RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 6, 2025 | marketbeat.comRAPT Therapeutics (RAPT) to Release Earnings on ThursdayMay 3, 2025 | marketbeat.comTCG Crossover Management LLC Buys Shares of 13,135,260 RAPT Therapeutics, Inc. (NASDAQ:RAPT)May 1, 2025 | marketbeat.com1,243,513 Shares in RAPT Therapeutics, Inc. (NASDAQ:RAPT) Purchased by Nantahala Capital Management LLCApril 30, 2025 | marketbeat.comForesite Capital Management VI LLC Invests $19.75 Million in RAPT Therapeutics, Inc. (NASDAQ:RAPT)April 30, 2025 | marketbeat.comIs RAPT Therapeutics (NASDAQ:RAPT) In A Good Position To Invest In Growth?April 18, 2025 | finance.yahoo.comRapt Therapeutics appoints Jessica Savage as VP, clinical developmentApril 17, 2025 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeKRON, INMB, MOLN, and RAPT Company DescriptionsINmune Bio NASDAQ:INMB$7.48 +0.12 (+1.56%) As of 12:08 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.Kronos Bio NASDAQ:KRON$0.67 0.00 (-0.37%) As of 12:06 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma. The company was incorporated in 2017 and is headquartered in San Mateo, California.Molecular Partners NASDAQ:MOLN$3.86 +0.28 (+7.68%) As of 11:56 AM Eastern This is a fair market value price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.RAPT Therapeutics NASDAQ:RAPT$0.90 -0.03 (-3.36%) As of 12:09 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Taiwan Semiconductor: Time to Buy After Strong NVIDIA Results? Archer Aviation Stock Steadies After Short-Seller Report e.l.f. Beauty Sees Record Surge After Earnings, Rhode Deal Apple Stock Could Rally After Tariffs Are Blocked By Court Hormel Stock Near Lows, But Tariff Relief Could Boost Outlook Salesforce’s Stock Price Presents an Opportunity to Buy NVIDIA Will Set a New High Soon, Then Keep Rallying, Here’s Why Goodyear Stock Surges 28% in 2025: Is More Growth Ahead? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
